<DOC>
	<DOCNO>NCT01435447</DOCNO>
	<brief_summary>Allogeneic stem cell transplantation potential curative therapy adult acute lymphocytic leukemia ( ALL ) . Based previous study , condition iv-busulfan ( iv-BU ) cyclophosphamide ( CTX ) feasible low toxicity transplantation mortality long-term survival comparable data report slightly high relapse rate particularly patient CR2 . In study , investigator aim improve condition Fludarabine + iv-BU use CTX stem cell transfusion consolidation ALL graft-versus-host disease ( GVHD ) prophylaxis .</brief_summary>
	<brief_title>Fludarabine/Busulfan Cyclophosphamide Conditioning Adult ALL</brief_title>
	<detailed_description>Patients adult acute lymphocytic leukemia ( ALL ) receive condition Fludarabine + iv-BU . The GVHD consist D+3 D+4 CTX stem cell transfusion . CSA add patient D+5 .</detailed_description>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>adult acute lymphocytic leukemia 1st second remission age 1860 year inform consent contraindication allogeneic transplantation : active infection , allergy FLu/Bu/CTX , liver renal function damage HLA match relate ( 6/6 ) , unrelated donor ( least 8/10 ) mismatch related donor ( haplo ) age le 18 year 60 year liver function/renal function damage ( 2 X upper normal range ) mental disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>conditioning</keyword>
	<keyword>fludarabine</keyword>
	<keyword>busulfan</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>adult</keyword>
</DOC>